Cocrystal Pharma (COCP) Cash & Current Investments (2010 - 2026)

Cocrystal Pharma has reported Cash & Current Investments for 17 years, with the latest figure at $4.8 million in Q1 2026.

• Quarterly Cash & Current Investments fell 31.62% year-over-year to $4.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.8 million (down 31.62% YoY) and the FY2025 annual result came in at $7.2 million, down 28.32% from the prior year.
• Cash & Current Investments fell to $4.8 million in Q1 2026 per COCP's latest filing, from $7.2 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $54.8 million in Q1 2022 and troughed at $150000.0 in Q2 2022.
• A 5-year average of $16.3 million and a median of $10.0 million in 2024 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2022 and 2023: Cash & Current Investments sank 99.78% in 2022, then soared 21562.67% in 2023.
• Over 5 years, Cash & Current Investments stood at $37.3 million in 2022, then dropped by 28.93% to $26.5 million in 2023, then sank by 62.23% to $10.0 million in 2024, then declined by 28.32% to $7.2 million in 2025, then sank by 32.61% to $4.8 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $4.8 million, $7.2 million, and $7.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.